Fermenta Biotech reported a sharp contraction in consolidated profitability for the quarter ended June 30, 2026, driven by declining revenues in its core bulk drugs segment and the absence of exceptional items that had boosted prior-year figures. Standalone net profit after tax (PAT) decreased 7.70% year-on-year (YoY) to ₹1,498.58 lakhs from ₹1,623.38 lakhs in Q1FY25. The consolidated net profit suffered a steeper decline of 55.80% YoY, falling to ₹953.15 lakhs compared to ₹2,160.17 lakhs in the corresponding period last year.

The Board of Directors approved the unaudited financial results on August 11, 2026, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. M/s. SRBC & Co. LLP, the statutory auditors, issued a limited review report with an unmodified opinion on both standalone and consolidated results. Managing Director Prashant Nagre signed off on the filings, which were submitted to the Bombay Stock Exchange and National Stock Exchange of India Limited.

Financial Performance Highlights

Revenue from operations showed weakness across both reporting structures. Standalone revenue from operations declined 6.0% YoY to ₹11,183.93 lakhs from ₹11,901.87 lakhs. On a consolidated basis, revenue dropped 10.60% YoY to ₹12,182.12 lakhs from ₹13,626.27 lakhs. Total income followed a similar trajectory, with standalone total income falling 8.70% to ₹11,673.59 lakhs and consolidated total income decreasing 12.90% to ₹12,619.50 lakhs.

The following table summarises key financial metrics across both standalone and consolidated reporting structures for the quarter:

Profit before tax for the standalone entity remained relatively stable at ₹2,014.58 lakhs, down slightly from ₹2,271.92 lakhs in Q1FY25. However, the consolidated profit before tax collapsed 47.70% YoY to ₹1,469.15 lakhs from ₹2,808.71 lakhs. This divergence highlights the impact of foreign subsidiaries and inter-segment dynamics on the group's overall performance.

What the Numbers Show

The disparity between standalone and consolidated results underscores the pressure on Fermenta Biotech's international operations. While the Indian parent company maintained its profit before tax levels, the consolidated entity faced a severe earnings compression. A key factor was the absence of exceptional items in the current quarter; the previous year's comparable period benefited from a ₹907.14 lakh recovery of provisions against receivables, recorded as an exceptional item but impacting the comparative base for growth calculations. Additionally, the consolidated segment results reveal that the 'Unallocated' category posted a net loss of ₹188.83 lakhs, compared to a profit of ₹210.03 lakhs in Q1FY25, further dragging down group profitability. The bulk drugs/chemicals segment, the primary revenue driver, saw its segment result decline 30.80% YoY on a consolidated basis from ₹2,752.23 lakhs to ₹1,905.05 lakhs, indicating margin erosion or volume declines in core products.

Fermenta Biotech Limited has successfully listed its equity shares on the National Stock Exchange of India Limited (NSE), effective August 4, 2026. The listing of 2,94,30,987 equity shares, each with a face value of ₹5, marks a significant expansion in the company’s capital market presence. Traded under the symbol FERMENTA and International Securities Identification Number (ISIN) INE225B01021, the move provides investors with additional accessibility and liquidity options, complementing the company’s long-standing listing on the Bombay Stock Exchange (BSE).

The dual listing strategy aims to broaden shareholder participation and enhance price discovery efficiency across India’s two major stock exchanges. Fermenta Biotech Limited, a manufacturer of Vitamin D3 API and nutritional ingredients, continues to maintain its BSE listing under Scrip Code 506414. The development aligns with the company’s efforts to improve visibility and engagement with a wider investor community, reflecting nearly five decades as a publicly listed enterprise.

Listing Details

Prashant Nagre, Managing Director of Fermenta Biotech Limited, described the NSE listing as a milestone in the company’s 75-year journey. He noted that the event reflects the firm’s resilience and commitment to innovation in nutrition, food fortification, and green chemistry. The listing ceremony included a bell-ringing event at the NSE’s Exchange Plaza in Mumbai, attended by board members and senior leadership.

Strategic Context

The decision to list on the NSE underscores Fermenta Biotech’s strategic focus on corporate governance and transparency. With operations spanning manufacturing facilities in Kullu, Dahej, and Tirupati, and an R&D center in Thane, the company serves over 400 customers in more than 60 countries. The expanded exchange presence is expected to support consistent shareholder engagement and reflect the company’s global scale in complex manufacturing and specialized solutions.